TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: FARE Peanut SLIT and Early Tolerance Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from participant's parent/guardian.~* Age 12-48 months of either sex, any race, any ethnicity.~* A peanut allergy diagnosis with a convincing clinical history of peanut allergy and a serum peanut-specific IgE \[UniCAP\] \> 0.35 kUA/L AND a positive skin prick test to peanut (\>3 mm than the negative control) OR are sensitized to peanut (based on a serum IgE \[UniCAP\] to peanut of \> 5 kUA/L) AND a positive skin prick test to peanut (\> 3 mm than the negative control) and no known history of ingestion of peanut.~* A positive DBPCFC to 1000 mg of peanut at enrollment.~Exclusion Criteria:~* History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or neurologic compromise (cyanosis or peripheral capillary oxygen saturation (SpO2) \< 92% at any stage, hypotension, confusion, collapse or loss of consciousness).~* Participation in any interventional study for the treatment of food allergy in the past 6 months.~* Known oat, wheat, or glycerin allergy.~* Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease.~* Severe asthma (2007 NHLBI Criteria Steps 5 or 6 - Appendix 2).~* Inability to discontinue antihistamines for skin testing and DBPCFCs.~* Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immunomodulator therapy (not including corticosteroids) or biologic therapy within the past year.~* Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers.~* Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease) which would make the subject unsuitable for induction of food reactions.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- Peanut (liquid peanut extract) SLIT (Type: EXPERIMENTAL): After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
- Placebo Glycerin SLIT (Type: PLACEBO_COMPARATOR): After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Triclosan Coated Suture in Obstetrical Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women with indicated cesarean delivery and who have signed a written consent.~Exclusion Criteria:~* Cases with incomplete follow up~* Breach of operative protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Triclosan coated suture (Type: ACTIVE_COMPARATOR): None
- Non coated suture (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory men 25 years of age and older presenting to Visit 1 with a bone mineral density (BMD) of at least 1.5 standard deviation (SD) below the corresponding normal young adult men average BMD (T score of -1.5 or lower), as determined from the manufacturer's database at any of the following regions of interest: total hip, femoral neck, or lumbar spine~* Have received glucocorticoid therapy at an average dose of at least 5.0 milligrams (mg) per day of prednisone or its equivalent for a minimum of 3 consecutive months immediately preceding screening (Visit 1), as determined by medical history.~* A minimum of 2 lumbar vertebrae (L) in the L-1 through L-3 region must be evaluable by quantitative computerized tomography.~* Normal or clinically insignificant abnormal laboratory values (as determined by the investigator) including serum calcium, parathyroid hormone (PTH) (1 84), and 25 hydroxyvitamin D concentrations, and alkaline phosphatase activity.~Exclusion Criteria:~* Presence of a mild, moderate, or severe spinal fracture in both the twelfth thoracic vertebra (T-12) and first lumbar vertebra (L-1), as determined by the central reading facility using the semiquantitative technique.~* Abnormal albumin-corrected serum calcium levels~* History of unresolved skeletal diseases that affect bone metabolism other than glucocorticoid-induced osteoporosis~* History of malignant neoplasms in the 5 years prior to Visit 2, with the exception of superficial basal cell or squamous cell carcinomas of the skin that have been definitively treated. Increased baseline risk of osteosarcoma; this includes patients with Paget's disease of the bone, previous primary skeletal malignancy, or skeletal exposure to therapeutic irradiation.~* Abnormal thyroid function not corrected by therapy~* Past and/or current treatment with certain medications.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
- Risedronate (Type: ACTIVE_COMPARATOR): Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects who have completed studies 998HB102 (NCT01027364) or 9HB02PED (NCT01440946) or other studies with rFIXFc~* Ability to understand the purposes \& risks of the study and provide signed and dated informed consent.~Key Exclusion Criteria:~* High-titer inhibitor (\>/=5.00 BU/mL)~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On-Demand (Type: EXPERIMENTAL): The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
- Prophylaxis (Type: EXPERIMENTAL): Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- Postmenopausal women \>40 years of age experiencing a minimum of 7 to 8 moderate to severe hot flushes per day or 50 to 60 moderate to severe hot flushes per week~Exclusion Criteria:~* The usual exclusion criteria for hormone therapy apply~* Intake of medications other than hormones affecting hot flushes

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5mg DRSP / 0.5mg E2 (BAY86-4891) (Type: EXPERIMENTAL): One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891) (Type: EXPERIMENTAL): One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
- Estradiol (E2 0.3mg) (Type: EXPERIMENTAL): One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective primary hip replacement~* Age 18 years or over~* Written informed consent obtained~Exclusion Criteria:~* Documented history or considered at increased risk of venous thromboembolism~* Subjects considered at increased risk of bleeding~* Surgery planned for contralateral hip at the same time or within 10 weeks after enrolment~* Concomitant use of anticoagulants/ antiplatelet agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Design and Evaluation of an Active Intervention for the Prevention of Non-contact ACL Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:The ages would range from 18 to 65. Both male and female subjects will be enrolled, and ethnic backgrounds would be mixed. Exclusion Criteria:(i) chronic lower body pain (ii) recent surgery of the lower or upper body (limitation of range of motion) (iii) previous history of ligament, meniscal, or chondral injury requiring surgery to the lower limb (iv) inability to complete jumping tasks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Activity Training with Feedback (Type: EXPERIMENTAL): Subject is tested prior to training and retested with feedback training designed to modify the mechanics of landing during jumping and running activities

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FLT-PET Imaging of Brain Tumors in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 21 years or less~* capable of achieving imaging without need for sedation or anesthesia (typically age 8 years or greater, but there is no lower limit for age for eligibility)~* Karnofsky Performance Status of 50 or greater in subjects age 12 years or greater, for age less than 12 years a Lansky play scale of 50% or greater~* Patients receiving steroids and/or anti-seizure medications are eligible~Exclusion Criteria:~* clinically active infection~* pregnancy or breast-feeding~* serious intercurrent medical illness~* require emergency surgical intervention that would be inappropriately delayed by FLT-PET imaging

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- New diagnosis of brain tumor (Type: EXPERIMENTAL): In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using \[18F\] FLT.
- Possible recurrent brain tumor (Type: EXPERIMENTAL): In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using \[18F\] PET.
- Brain tumor response to chemotherapy (Type: EXPERIMENTAL): In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using \[18F\] FLT before the start and after two cycles of chemotherapy.~Despite much effort and working with referring physicians at multiple hospitals, enrollment in this arm remained low, and it seemed unlikely that meaningful enrollment would be accomplished. A revised study plan was submitted to the granting agency and FDA, and this arm was closed to further enrollment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Intervention and Vascular Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Adults should have a relative risk (RR) of \> 1.5 of developing cardiovascular disease (CVD) based on presenting with at least one recognised risk factor for CVD:~* total cholesterol (TC) \> 6.0 mmol/l~* HDL cholesterol (HDLC) ≤ 1.0 mmol/l male, ≤ 1.3 mmol/l female~* Glucose ≥ 6 mmol/l~* Stage 1 hypertension or above i.e. a systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg~* BMI 28-35 kg/m2~* waist \>102 cm male or \> 84 cm female~* Adults with a first degree relative with either a history of premature CVD - age of onset younger than 55 y in fathers, sons or brothers or younger than 65 y in mothers, daughters or sisters, or type 2 diabetes.~Exclusion Criteria:~* having suffered a myocardial infarction/stroke in the past 12 months~* diabetic (diagnosed or fasting glucose \> 7 mmol/l) or suffer from other endocrine disorders~* suffering from renal or bowel disease or have a history of choleostatic liver or pancreatitis~* on drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation~* no history of alcohol abuse~* planning or on a weight reducing regime~* taking any fish oil, fatty acid or vitamin and mineral supplements~* pregnant, lactating or planning a pregnancy~* smokers

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- high saturated fat diet (Type: ACTIVE_COMPARATOR): None
- high monounsaturated fat diet (Type: EXPERIMENTAL): None
- high n-6 polyunsaturated fat diet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Depression Interventions After Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized for ACS defined as unstable angina or MI~* BDI greater or equal to 10 and \< 15 2-6 months post-ACS on each of 2 occasions, or BDI greater than 15 on one occasion~* Age at least 35 years~* Fluent in English or Spanish~* Able to complete baseline assessment within 2-6 months of index ACS event~* Able and willing to provide informed consent~Exclusion Criteria:~* Presence of non-cardiac condition likely to terminate fatally within 1 year~* Inaccessibility for intervention or follow-up (e.g., plans to move from the area)~* Cognitive impairment~* Need for immediate psychiatric intervention (i.e., requiring hospitalization or psychiatric intervention within 72 hours)~* Suicidal ideation~* Major psychiatric co-morbidity (current or by history) including active psychosis, bipolar disorder, or overt personality disorder~* Active substance abuse or dependency~* Chronic renal failure (receiving chronic dialysis treatment, or estimated glomerular filtration rate...\[eGFR\] \< 30 ml/min/1.73 m2) or moderate/severe liver disease (e.g., esophageal varices, portal hypertension, encephalopathy, GI bleeding)~* Participation in another clinical trial for the treatment of depression.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Referred Care (Type: ACTIVE_COMPARATOR): Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
- Stepped Care (Type: EXPERIMENTAL): Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Probands who meet the following criteria will be enrolled:~Menses \< 6 per year without confounding meds Not taking confounding medications at the time of hormone analysis, willing to be off confounding medications for required washout period, or able to provide documentation of hyperandrogenemia (without hyperprolactinemia or evidence of non-classical adrenal hyperplasia) with past laboratory tests during a time when not taking confounding medications Total Testosterone \>58 ng/dl or bioavailable testosterone \>15 ng/dl Prolactin \<25 ng/ml Baseline 17-OHP \<3 ng/ml (and stimulated 17-OHP \<10 ng/ml if subject is studied on-site)~Control women who meet the following criteria will be enrolled:~History of completely regular menstrual cycles. No history of hirsutism or alopecia. Control women will have a blood sample obtained 3-6 months after they have stopped lactating and resumed regular menses to ensure that they have normal T, uT and DHEAS levels.~Any pregnant woman who develops gestational diabetes will be excluded from the analysis.~To exclude disorders associated with insulin resistance, control subjects will have no personal history of hypertension or hypertriglyceridemia and no first-degree relative with Type 2 DM~Exclusion Criteria:~* history of gestational diabetes mellitus, eclampsia, pre-eclampsia or any medical disorders complicating their pregnancies.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CD or UC based on endoscopy and pathology~* 18 years or older~* Clinical remission, based on a Harvey Bradshaw Index (HBI) score ≤4 or a Partial Mayo (PM) score ≤2, for CD and UC~* Scheduled IFX maintenance treatment, regardless of interval/dosing~Exclusion Criteria:~- Dilatation or resectional surgery because of stenotic IBD in the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PRECISION dosing (Type: EXPERIMENTAL): Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
- Conventional dosing of Infliximab (Type: NO_INTERVENTION): Infliximab 5 mg/kg every 8 or 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Infants between 42 and 98 days of age (approximately 2 months) at the time of enrollment.~Exclusion Criteria:~* Previous vaccination with pneumococcal vaccine,Haemophilus influenzae type B (Hib) conjugate vaccine, meningococcal type C conjugate vaccine, or diphtheria, tetanus, pertussis, or poliovirus vaccines.~* Previous anaphylactic reaction or allergy to any vaccine~* Contraindication to vaccination~* Known or suspected immune deficiency or immune suppression~* Major known congenital malformation or serious chronic disorder~* Significant neurological disorder~* Participation to another study

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: f

Study Arms:
- Group 1: Preterm infants (Type: ACTIVE_COMPARATOR): Infant born at \< 37 weeks of gestation.
- Group 2: Term infants (Type: ACTIVE_COMPARATOR): Infants born at ≥ 37 weeks of gestation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete